Directory · KR
Biotechnology Research in South Korea
A register of firms and the professionals working at them in the Biotechnology Research sector based in South Korea. Browse the public index, then filter or export on Kipplo.
Companies
299 on file
Genoplan
Genoplan, a startup specializing in DNA testing, analyzes user’s saliva to conduct genetic analysis and give life style advice tailored for each user, including diet, health food, work-out, and cosmetics. The company was incorporated in 2014, and has operations at Seoul, Korea and Fukuoka and Tokyo, Japan. AI.
11 to 50 staff
Neuracle Science
Over the past decades, focusing on a battery of conventional genes/proteins involved in the neurodegeneration has been disappointing in the field of neurodegenerative therapeutics. With the scientific responsibility and integrity, Neuracle Science is a clinical stage biotech company specialized in the development of breakthrough therapies for those who are living with serious and devastating neurodegenerative diseases. We provide a foundation for disease-modifying treatments for neurodegenerative diseases, discovering a completely novel and invaluable gene/protein target with unknown significance using non-biased study. Neuracle Science is based in Seoul, South Korea. We were founded in 2015 by scientific leaders in neuroscience, bioinformatics-based drug discovery, GPCR-mediated signaling, and antibody drug.
11 to 50 staff
Optolane Technologies Inc
Optolane is an innovator in the healthcare and diagnosis industry, developing a POCT molecular and immunoassay diagnostic platform embedded in a bio application-specific CMOS sensor device. We offer a sophisticated diagnostic platform to the disease diagnosis and preventive home healthcare market. Our new diagnosis systems are small but simple, fast and smart.
51 to 200 staff
Portrai Inc
The Solutionist of Pharmaceutical industry Portrai leverages spatial transcriptomics to accelerate the drug discovery and biomarker discovery process. We co-develop the drugs with co-license and provide Platform-as-a-service to pharmaceuticals and biotechs. Radioligand therapy and Antibody-drug conjugate in oncology and brain diseases are therapeutic modalities of interest. AI pathology combined with spatial transcriptomics is our novel approach to make a scalable solution for companion diagnostics. 🟣 PortraiTARGET: Find the target locations that show the best distribution in the tissue and prioritize the target to develop. 🟣 PortraiDRUG & PortraiMIX: Visualize and quantify the drug distribution within the tissue slide to investigate the drug really goes to the target location well. It can be used for drug optimization and drug licensing deals. 🟣 PortraiMOA: Shows the overall changes of RNA expression comparing the spatial transcriptomics data between control and treated group to find out whether the drug works well in that location. 🟣 PortraiTME: Show biomarker distribution in the patient tissues to select the right patients for the drug by integrating H&E slide image and spatial transcriptomics data. It can predict immune/stromal cell proportions and spatial distribution from H&E slide with decent correlation, and even more it could be scaled up to other various biomarkers.
11 to 50 staff
Prazer Therapeutics
Prazer Therapeutics is a biotechnology company pioneering innovative therapeutics for various intractable diseases using rational drug design and next-generation targeted protein degradation (TPD) platform called SPiDEM. Our SPiDEM-based drug candidates for neurodegenerative diseases, cancers and inflammatory diseases have demonstrated superior pharmacokinetics and efficacy as well as reduced drug resistance compared to currently available TPD technologies. Our pipeline also encompasses anti-viral therapeutics to treat chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) as well as acute lung inflammation caused by coronaviruses, influenza viruses and respiratory syncytial virus (RSV).
11 to 50 staff
Biorchestra Co., Ltd
BIORCHESTRA is an innovative biotech company focusing on research and development of ribonucleic acid (RNA) based therapeutics. Our goal is to change the therapeutic paradigm from treating the symptoms to providing fundamental cure of the diseases. As we are making steady progress in the clinical development, we seek global partners to collaborate in the areas of research and development (R&D) and the commercialization.
51 to 200 staff
Exocobio
The First and Leading Cosmeceutical/Biopharmaceutical Company based on Exosomes EXOsome COsmeceuticals & BIOpharmaceuticals
51 to 200 staff
Primoris International Co., Ltd
Primoris International develops simple but high-quality of effective product as an innovative First Mover that leads the Exosome market. Completion of ‘Reverse Aging’, We carry out a variety of businesses ranging from raw materials to the medical field with the Exosome that reverses aging.[Medical Aesthetic]#P198 ExoHealer, CURESTEM; Exosome Skin Booster #P198 ExoNature; Plant Exosome Skin Booster #NXA ExoFila; Exosome Filler #ExoPLA; Microwave Plasma Device [Derma Cosmetics]#SKINPHIILIA; Cosmetical Aesthetic Exosome Cosmetics #LABOSTEM, GD11, benestem; Stem Cell Exosome Cosmetics #57N; Began Cosmetics [Heritage Ingredients]#USC1994; Human Umbilical Cord Blood Stem Cell Exosomes #ASC1994; Human Adipose Stem Cell Exosomes #PSC1994; Plant Stem Cell Exosomes Instagram; primoris.medical.official p198.official Youtube; exosomeTV [Sales Contact Point] contact@primoris.co.kr
51 to 200 staff
Rapigen, Inc
We are continually challenging ourselves to become a leading company specialized in in-vitro diagnostics and dedicated to creating value for human health innovation. Rapigen Inc. was the first to successfully commercialize rapid diagnostics using Black Gold Nanoparticles and a dual-color system. We have leveraged this innovation through successful collaborations with various international organizations, including the WHO, Bill & Melinda Gates Foundation, Global Fund, PATH, and FIND, on numerous impactful projects. We now offer around 70 products for human and veterinary use, exporting to over 52 countries worldwide. Since 2023, we have confidently expanded into the molecular diagnostics field, manufacturing and supplying a wide range of PCR reagents and developing diagnostic kits for various infectious diseases. We understand the importance of promoting healthier lives, which is why in addition to diagnostics, we are committed to providing health screening centers and food-related solutions.
201 to 500 staff
Avelos Therapeutics
Avelos Therapeutics develops next-generation targeted oncology medicines with high unmet need, to a wider range of possibilities with present and future applications, especially in the areas of cell cycle regulation, undruggable cancer targets, and DNA damage response with a primary focus on synthetic lethality.
11 to 50 staff
Biosensor Laboratories, Inc
BioSensor Laboratories, Inc, a biotech startup based in Korea, introduces an innovative TDD(Transdermal Drug Delivery) technology applicable to both fields of cosmetics and pharmaceuticals. Our technology which goes by the brand of ‘Tissue X’ has made possible a professional dermatological procedure thorough a small sized patch. Tissue X is an innovative technology in that macromolecules that couldn’t be delivered to the epidermis(inner skin) by conventional cosmetics - such as hyaluronic acid(HA) and Argireline - can be successfully and stably delivered. Also API's that could be delivered only through subcutaneous injection such as exenatide and teriparatide can now be delivered through this small sized patch. Biosensor Lab is also developing an electro-chemistry POCT(Point of Care Testing) technology that provides an effective sensor solution to pool management and food safety.
11 to 50 staff
Cj Bio Taste & Nutrition
CJ BIO seeks to take on new and bold challenges in innovative future ingredients for wellness food and beverage, nutrition solutions, and alternative and cultured protein (meat). CJ BIO will be committed to strengthening customized solutions for “nrich”, natural premium food ingredient, and accelerating proprietary specialty nutrition solution business so that it can hasten its transformation into a high-tech Total Solution Provider in Taste & Nutrition. We, CJ BIO, will continue to provide visionary solutions for human health and nature by utilizing the value added technology and market insights.
501 to 1000 staff
Ck Regeon
CK Regeon Inc. is a biotech-based company founded in October, 2016 aiming to develop First-in-Class drugs addressing unmet medical needs. The company was established on the basis of the Transnational Research Center for Protein Function Control (TRCP/ ERC), a government-supported drug development institute, which has been directed by the CEO of CK Regeon Inc, Dr. Kang-Yell Choi, for more than 10 years. The excellence of their previous R&D achievements of his laboratory was proven by several times selections of the nationally honorary awards such as “National R&D Excellence of 100” and “excellent basic research 50”. He also successfully performed major national drug development projects such as “Korea Drug Development Fund” and “National OcoVentrue”. Currently, on the basis of the previous outcomes from TRCP, CK Regeon Inc. has been performing R&D for development of drugs targeting Wnt/β-catenin pathway related with regeneration. CK Regeon Inc. especially interested in the diseases suppressed regeneration in damaged and disease status tissues by suppression of the Wnt/β-catenin signaling. CK Regeon Inc. identified cytosolic overexpression of CXXC5, a negative feedback regulator of the Wnt/β-catenin signaling, as a major disease marker for the targeting diseases not only by usage of the disease model, but also by characterization of patient tissues. The aiming drug candidates revels therapeutic effects by restorative activation of the Wnt/β-catenin signaling followed by recovery of the tissue regeneration system. The drug candidates under the development by CK Regeon Inc. selectively function to the patients who overexpressed CXXC5, but not to healthy persons maintain low level of CXXC5 especially at cytosol. The targeting diseases include obesity, diabetes, and nan-alcoholic steatohepatitis (NASH), as well as the topically applicable drugs promoting hair growth and wound healing.
11 to 50 staff
Foodyworm Inc
Foody Worm is a Korean company dedicated to promoting the happiness of animals, people, and the earth through innovative insect-based solutions. We envision a future where insects serve as a sustainable substitute for meat protein, bringing about positive environmental and health impacts. Through our relentless pursuit of this vision, we have developed groundbreaking techniques for mass automatic breeding of insects, enabling us to achieve standardization of raw materials. This ensures consistent quality and scalability in our insect-based products. At Foody Worm, we are driven by our commitment to zero-waste agricultural food circulation and the development of sustainable protein sources. By harnessing the potential of insects, we are actively working towards reducing the ecological footprint associated with traditional meat production. Join us in our mission to create a more sustainable world, one where insects play a crucial role in revolutionizing the food industry. Together, we can pave the way for a healthier and happier future.
11 to 50 staff
Proxihealthcare Inc
Founded in 2019 in Seoul, South Korea, by YoungWook Kim, Ph.D, ProxiHealthcare Inc. is at the cutting edge of biotech innovation with its patented TROMATZWAVE® technology that focuses on combating the effects of harmful biofilms on human health and the broader environment. This state-of-the-art technology, stemming from Kim's Ph.D. research at the University of Maryland, uses bioelectric microcurrent waves to disturb the metabolism and weaken the protective layer of biofilms. Under Dr. Kim's leadership, the company has filed an impressive dossier of 122 intellectual properties, offering avant-garde solutions in healthcare, automotive, and maritime applications - from medical devices to biofouling prevention. Strategically headquartered in Seoul with an advanced in-house research lab (PAIST) and a manufacturing base in Ulsan, ProxiHealthcare Inc. has grown rapidly to over 40 dedicated professionals in South Korea. In 2022, the biotech startup opened a corporate branch (ProxiHealthcare USA Inc.) in Fort Lee, New Jersey, to establish its presence on a global scale and emphasize its dedication to being a global leader at the forefront of healthcare technology.
11 to 50 staff
Solgent Co., Ltd
SOLutions for GENetic Technologies [About Company] Located in South Korea, SolGent was founded in and has been growing for over a decade based on our strong relationships with valued customers who trust in our quality products. Since our foundation, SolGent has been manufacturing important raw materials for molecular biology, such as DNA polymerase. Utilizing our expertise, SolGent launched a series of molecular diagnostic kits in 2012. Now, as well as distributing throughout the world, we are providing our kits and raw materials to diagnostic and research related institutes based in korea like the KCDC(Korea Centre for Disease Control), Korea National Institutions and Hospitals. Solgent has a well-established manufacturing center with its own research institute equipped with state-of-the-art facilities, covering in Daejeon, South Korea. All products including the molecular diagnostic kits are manufactured in house and adhere to global standards ISO9001:2008 and ISO13485:2003. Many of our diagnostic kits have received CE-IVD certification with additional products launching in late 2015 currently processing certification.[Products]- PCR enzyme - Diagnostic kit * If you want to know more about our products, visit our website: [Business Area]- Molecular Diagnostics - Research Reagents - Sequencing Analysis [Achievement & Rewards]- ISO9001:2008 - ISO13485:2003 - CE certification for molecular diagnostics * 100% QD Double check system for all products.[Additional Info]- - solgent.tradekorea.com
51 to 200 staff
Abion Inc
ABION is the Korean drug discovery company with the pioneering spirit. Established in 2007, Abion was the first Korean biopharma to advance the concept of precision oncology. The company has robust pipeline for drug candidates in preclinical stage, clinical phase 1 and phase 2 to treat lung cancers and infectious diseases and is actively seeking research and clinical partnerships. Abion Youtube channel
11 to 50 staff
Btgin Co., Ltd
BTGin Co, Ltd. has been proudly established as a Bioventure company in Daejeon, Korea for human health and happiness by developing Biotechnology with ginseng products like ginsenosides and producing new medical materials in 2002. Recently due to the strong possibility of pharmaceutical use for ginseng and ginsenosides, the world-wide trade market of ginseng is remarkably increasing and more competitive. To use the main component of ginseng for new medicine and nutraceuticals, BTGin has been developed the enzyme technology by which new ginsenosides and effective ginseng components which have been produced through the transformation of ginseng structure. BTGin is a sole company which has a specific technology to manufacture and modify more than 30 pure single ginsenosides including Rd, F1, F2, Rg3, Rg2, Rh1, Rh2, Mc, Mc1, Compound K, Y, O, aglycone PPD, PPT in a mass production. Furthermore, BTGin Co, Ltd. possesses its own technology to examine the qualities of various ginseng products. Also BTGin is manufacturing various glyco-products such as functional food and cosmetic materials by applying its high technologies. Based on the management motto “Creation of unlimited value through free competition”, BTGin will be the leader of biotechnology in the world.
11 to 50 staff
Chungwoo
Our company thinks the customer with priority. our company thinks you as the most valuable customers to us. It will finish the hazard best always. Thank you! We are the manufacturer of electro medical / beauty instruments and general distributor for medical beauty products. History 2001 Foundation of CHUNG WOO MEDICAL Co,Ltd 2002 Medical Implement Manufacturing License (No.1302) Acquired Registered Patent -ICT Increased Capital - 0.4 million(US$) Participated Medical Equipment Show in Busan, Korea 2003 Participated Medical Aesthetic Equipment Show in Seoul, Korea Acquired Designed Quality grade (KMAC) Registered Research Development Department Be awarded GOOD DESIGN (KIDP) Participated Medical Equipment Show in Busan, Korea 2004 Registered Venture Company (New Technology) Participated Medical Equipment Show in Busan, Korea 2005 Established Specialty Sales Division for Personal beauty and Skincare device Utility Model Registration od Obesity Therapy Stimulator 2006 Approved the settlement of R&D center by Korea industrial Technology Association Acquired ISO13485:2003 2007 Extend Beauty Business Division for domestic professional beauty salon & clinics Participated Medical Aesthetic Equipment Show in Seoul, Korea Participated Diet Beauty Fair 2007, Japan Participated ZDRVOOKHRANENIYE 2007 in Moscow, Russia 2008 Participated Tokyo Health Industry Show 2008, Japan Participated Medical Aesthetic Equipment Show in Seoul, Korea
11 to 50 staff
Gemvax & Kael
Since 2008, GemVax & KAEL has operated as a cutting-edge research and development company developing proprietary peptide drug, GV1001, for treatment against various cancers and neurodegenerative disease including Alzheimer's disease and Progressive Supranuclear palsy. The fundamental driving purpose of our innovative pharmaceutical research is to facilitate significant improvements to human life through the introduction of advanced medical technology and innovation rooted in advanced scientific measures. At GemVax, we take pride in our proactive approach to medical research, and our progressive peptide-drug focused advancements have played a crucial role in the incessant global battle against incurable disease.
51 to 200 staff
Genemedicine
GeneMedicine(GM) is a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies, aiming to transform the therapeutic outcomes for cancer patients. Using our proprietary adenovirus platform, we're developing several pipeline products that can be intratumorally and intravenously administered to selectively attack and eradicate tumor cells as well as potently stimulating multiple arms of antitumor immune response. Our viral immunotherapy has proven effective as both a standalone therapy and in combination with current standard of care, including immune checkpoint inhibitors (ICI). Intratumoral administration of GM oncolytic adenovirus offers several advantages over competitor products;(1) higher level of virus accumulation and localization in tumor tissues and (2) lower off-target systemic exposure, ultimately exerting potent therapeutic effect with minimal systemic toxicity. Our pipeline can effectively treat wide range of tumor types, including breast cancers (triple-negative and hormone receptor-positive), prostate cancer, melanoma, and non-melanoma skin cancer, desmoplastic cancers (like pancreatic cancer), and injectable visceral tumors that have spread to the liver, such as metastases from colorectal and lung cancer. To treat metastatic and recurrent cancers in late-stage cancer patients, we've developed systemic delivery platform for oncolytic viruses that avoids rapid blood clearance and inactivation by the immune system and various blood components. GM’s potent multi-armed oncolytic viral platform GM-OAd mediated oncolysis results in immunogenic cell death to trigger robust antitumor immune activation and memory formation to ensure long-term therapeutic benefit against cancer. GM has a highly scalable, low cost manufacturable platform offering highly versatile, innovative treatment options for patients with advanced or metastatic tumors.
11 to 50 staff
Glory Biotech Corp
Glory Biotechnologies Corp. is an expert innovative research and development company dedicated to the development of new diagnostics systems for the diagnosis of incurable diseases and providing complete solutions for the Biotechnology Industry. Glory Biotechnologies Corp. was established as a biotech venture in Seoul, 2014. Since its establishment, the company has kept on gaining ground in conjunction with different research projects such as KOICA (CTS Program) by employing aspiring experts and ambitious professionals to develop diagnostic instruments, providing the LIMS, Lab automation, Data management and Biobanking, Molecular biology reagents and solutions for Pharmaceutical industries. Our slogan “For giving Better Life” is a clear indication of our establishing mission, and our aim is to discover, create, and effectively showcase or change to highlight new restorative applicant substances through persistent innovative work, thereby contributing to the welfare of humanity. We have kept on building a solid patent portfolio by gathering significant intellectual property, which is essential in the inventive economy. The development of new diagnostic systems is a high-hazard business that requires huge time and venture. It is not an easy job for extraordinary researchers and companies to develop a new diagnostic instrument all alone. To accomplish the demand in this era of specialized union and redid prescription, Glory Biotechnologies Corp. kept on extending its joint research and innovation, improvement by creating networks with driving domestic bio-innovation organizations international biotechnology based company. Glory Biotechnologies Corp. will continually endeavor to grow new diagnostic instrument that is very much perceived in the worldwide medical instrument market. We will also continue to further strengthen our R&D capabilities as a global leader. Kindly, give your support to Glory Biotechnologies Corp. of a developing invisible champion.
11 to 50 staff
Greengene
Our unique and proprietary platform technology - Organelle(Chloroplast and Mitochondria) gene editing - enables us to edit RuBisCo, a key enzyme in photosynthesis and the most abundant protein in the world. We believe that our research and vision can lead to the ultimate key solution for climate crisis and food scarcity.
11 to 50 staff
Imbdx
IMBdx is a precision oncology company committed to advancing safe and accurate cancer diagnosis, monitoring, and screening. We have developed a minimally-invasive liquid biopsy technology that detects cancer and monitors its progression with just a single blood draw. Our AlphaLiquid® test provides comprehensive genomic profiling (CGP) of tumors, identifying key mutations and offering personalized treatment options, including matching therapies and relevant clinical trial opportunities. In addition to AlphaLiquid®, we offer CancerDetectTM, a minimal residual disease (MRD) test that detects trace amounts of cancer cells remaining after treatment, allowing for early relapse detection. We also provide CancerFindTM, a multi-cancer early detection (MCED) test that screens for multiple types of cancer at once, even in asymptomatic patients, enabling earlier and more effective intervention. Since beginning our research in 2014, our goal has been to make cancer diagnosis more accessible and affordable for patients worldwide. For more information, please visit or contact us at support@imbdx.com.
51 to 200 staff
